Glenmede Trust Co. NA Has $9.48 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALO

Glenmede Trust Co. NA boosted its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 22.4% in the 1st quarter, Holdings Channel.com reports. The firm owned 146,717 shares of the biopharmaceutical company’s stock after acquiring an additional 26,851 shares during the quarter. Glenmede Trust Co. NA’s holdings in Halozyme Therapeutics were worth $9,482,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in HALO. Arrowstreet Capital Limited Partnership increased its holdings in shares of Halozyme Therapeutics by 29.5% during the third quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock worth $241,337,000 after buying an additional 749,484 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Halozyme Therapeutics by 1.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,104,157 shares of the biopharmaceutical company’s stock valued at $141,613,000 after acquiring an additional 25,731 shares in the last quarter. Norges Bank bought a new stake in Halozyme Therapeutics during the 4th quarter worth $128,201,000. William Blair Investment Management LLC bought a new stake in Halozyme Therapeutics during the 4th quarter worth $124,031,000. Finally, Federated Hermes Inc. increased its holdings in Halozyme Therapeutics by 8.5% in the 4th quarter. Federated Hermes Inc. now owns 1,574,621 shares of the biopharmaceutical company’s stock worth $105,972,000 after purchasing an additional 123,917 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Buying and Selling

In other Halozyme Therapeutics news, Director Mahesh Krishnan sold 7,304 shares of the stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the sale, the director owned 14,462 shares of the company’s stock, valued at approximately $1,084,650. This represents a 33.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $76.71, for a total transaction of $124,653.75. Following the transaction, the director owned 42,044 shares of the company’s stock, valued at approximately $3,225,195.24. The trade was a 3.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 72,477 shares of company stock valued at $5,102,643 over the last ninety days. 2.50% of the stock is owned by company insiders.

Halozyme Therapeutics Stock Down 0.3%

Shares of NASDAQ:HALO opened at $82.27 on Tuesday. The firm has a market cap of $9.76 billion, a P/E ratio of 29.59, a P/E/G ratio of 0.34 and a beta of 0.85. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81. Halozyme Therapeutics, Inc. has a 12-month low of $58.67 and a 12-month high of $84.44. The business has a fifty day simple moving average of $74.80 and a 200 day simple moving average of $70.99.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The firm had revenue of $376.71 million for the quarter, compared to the consensus estimate of $358.60 million. During the same period in the previous year, the business earned $1.11 EPS. The business’s quarterly revenue was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Analysts predict that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current year.

Wall Street Analysts Forecast Growth

HALO has been the subject of several research reports. Weiss Ratings upgraded Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. HC Wainwright reiterated a “buy” rating and issued a $95.00 price objective on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. Finally, Morgan Stanley cut their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Eight research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $81.60.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.